Buscar

Estamos realizando la búsqueda. Por favor, espere...

Innovative therapeutic approaches in non-alcoholic fatty liver disease: when knowing your patient is key

Abstract: Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis may result from the dysfunction of multiple pathways and thus multiple molecular triggers involved in the disease have been described. The development of NASH entails the activation of inflammatory and fibrotic processes. Furthermore, NAFLD is also strongly associated with several extra-hepatic comorbidities, i.e., metabolic syndrome, type 2 diabetes mellitus, obesity, hypertension, cardiovascular disease and chronic kidney disease. Due to the heterogeneity of NAFLD presentations and the multifactorial etiology of the disease, clinical trials for NAFLD treatment are testing a wide range of interventions and drugs, with little success. Here, we propose a narrative review of the different phenotypic characteristics of NAFLD patients, whose disease may be triggered by different agents and driven along different pathophysiological pathways. Thus, correct phenotyping of NAFLD patients and personalized treatment is an innovative therapeutic approach that may lead to better therapeutic outcomes.

 Fuente: International Journal of Molecular Sciences, 2023, 24(13), 10718

 Editorial: MDPI

 Año de publicación: 2023

 Nº de páginas: 28

 Tipo de publicación: Artículo de Revista

 DOI: 10.3390/ijms241310718

 ISSN: 1661-6596,1422-0067

 Url de la publicación: https://doi.org/10.3390/ijms241310718

Autoría

MARTA ALONSO PEÑA

BARRIO AZACETA, MARÍA DEL

PELETEIRO VIGIL, ANA

JIMÉNEZ GONZÁLEZ, CAROLINA

ALVARO SANTOS LASO

PAULA IRUZUBIETA COZ